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Summary
Mannan-oligosaccharides (MOS), as zootechnical feed ingredients, are widely used in animal nutrition. MOS has been com-
mercially available since the launch of Bio-Mos® in the early 1990’s and has a substantial body of scientiﬁc papers and prac-
tical examples of its efﬁcacy. Since 1999, the use of MOS in animal feed has become more prominent, mainly due to the
European ban on prophylactic antibiotic growth promoters in animal feed. MOS, with its ability to bind and limit the colon-
isation of gut pathogens, has proven to be an effective solution for antibiotic-free diets, as well as providing support for
immunity and digestion. MOS has been shown to improve gastrointestinal health, thus improving wellbeing, energy levels
and performance. Most MOS products, particularly those that have been scientiﬁcally developed, derive from the cell wall
of the yeast, Saccharomyces cerevisiae. In 2009, a mannose-rich fraction (MRF) product was commercially launched as a ‘second
generation’ of these MOS-type products, with enhanced activities in immune modulation and intestinal health. The purpose of
this paper is to review the existing data on the beneﬁts of MOS for all species of animals, discuss its mechanisms of action in
vivo and compare the beneﬁts of using second generation MRF to original MOS.
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Functionality of MOS
In the yeast cell wall, mannan oligosaccharides (MOS) are
present in complex molecules that are linked to a protein
moiety. There are two main locations of MOS in the cell
wall of Saccharomyces cerevisiae (Stewart et al., 1998); either
attached to cell wall proteins (Lesage et al., 2006) as
part of –O and –N glycosyl groups or as elements of lar-
ger α-D-mannanose polysaccharides (Kath et al., 1999),
which consist of α-(1,2)- and α-(1,3)- D-mannose
branches (from 1 to 5 ring structures in length), which
are attached to extended α-(1,6)-D-mannose chains
(Vinogradov et al., 1998). This speciﬁc combination of
various functionalities involves MOS-protein conjugates
and highly hydrophilic, but variable, ‘brush like’ struc-
tures that have attachment ability for various receptors
within the digestive tract (Mansour et al., 2003), and on
the surface of bacterial membranes (Wellens et al.,
2008). This allows MOS to effectively bind the thread-
like ﬁmbriae on pathogenic bacteria (Firon et al., 1983;
Oyofo et al., 1989a), rendering them unable to attach to
the gut wall, preventing their stabilisation and subsequent
colonisation and multiplication to disease-causing levels
(Figure 1). MOS-protein conjugates are involved in inter-
actions with the animal’s immune system and can
enhance immune system activity (Wismar et al., 2010;
Che et al., 2011) and it is thought that they play a role
in antioxidant and antimutagenic defences (Krizkova
et al., 2006).
In addition, research comparing commercial MOS to
AGP’s has shown that it can effectively improve the
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integrity of the intestinal mucosa in broilers (Spring et al.,
2000; Iji et al., 2001; Baurhoo et al., 2007). Cheled-Shoval
et al. (2011) studied the effect of in ovo administration of
MOS on small intestine development during the pre- and
post-hatch periods in chickens, ﬁnding increases in villi
area and organisation, crypt depth and number of goblet
cells per villus on day of hatch in MOS treated birds
(Figure 2).
Effect of MOS on animal performance
In animals, a healthy gut environment is a major driver of
efﬁcient feed utilisation, which is important for sustain-
able production and for the efﬁcient use of feed materi-
als. Prior to the ban in 1999 due to concerns about the
build-up of antibiotic resistance in humans who con-
sumed the meat of these food-producing animals,
AGPs were routinely added to animal diets to ensure
intestinal health. This change promoted the use of feed
ingredients as natural replacements of AGPs. Based on
a large body of research, MOS established itself as a
one of the more important natural additives for this
role in farm animal production. The effect of MOS on
animal performance has been analysed in several
meta-analyses (statistical analyses of ﬁnal reports from
trials that essentially contain the same experimental treat-
ments) for poultry (Hooge, 2004a, 2004b; Sims et al.,
2004; Baurhoo et al., 2007; Yang et al., 2008a; Horgan
et al., 2010), pigs (Iji et al., 2001) and calves (Milk
Products, 2007). These analyses reported consistent
improvements of gut health and the consequential
improvement in performance with MOS.
MOS and bacterial colonisation
The initial interest in using MOS to protect gastrointes-
tinal health originated from work done in the late
1980s. At this time researchers looked at the ability of
mannose, the pure single unit of the complex sugar in
MOS, to inhibit salmonella infections. Various studies
showed that salmonella can bind via type-1-ﬁmbriae
(ﬁnger-like projections) to mannose. The binding to
mannose reduced the risk of pathogen colonisation in
the intestinal tract (Oyofo et al., 1989a,b,c). Different
forms of mannose-type sugars interact differently with
type-1-ﬁmbriae. The α-1,3 and α-1,6 branched mannans
present in the cell wall of Saccharomyces cerevisiae are par-
ticularly effective at binding pathogens (Firon et al.,
1987). Based on the in vitro ﬁndings, Newman et al.
(1993) conducted trials to determine any beneﬁcial
Figure 1. Blocking bacterial attachment and thus inhibiting host colonisation
by MOS
Figure 2. Villi without MOS supplementation (left) and villi with MOS supplementation (right). Pictures courtesy of S. Collett, University of Georgia, USA
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effects of MOS in calves affected by salmonella infec-
tions, and reported improved performance.
In controlled studies with chickens, a reduction in the
prevalence and concentration of different strains of
Salmonella spp. as well as E. coli was reported (Spring
et al., 2000). Reductions in E. coli were also reported by
other researchers (Dimitroglou et al., 2009).
Salmonellosis is a disease that requires an efﬁcient con-
trol system, which includes dietary measures, which is
critical in order to produce safe food for human consu-
mers. Further research has shown a reduction in Clostridia
spp., another common intestinal pathogen (Sims et al.,
2004; Biggs et al., 2007) which has a major impact on
food animals. The effects of MOS on controlling
E. coli and Salmonella spp. are quite consistent. By blocking
the attachment and colonisation of the intestine by gram
negative pathogenic bacteria with MOS, the autogenous
population is able to ﬂourish, making the gut more efﬁ-
cient, and liberating more nutrients for lean tissue growth
and immunity in the host animal. However, reported
effects on promoting beneﬁcial bacteria, such as
Lactobacilli and Biﬁdobacteria are more variable (Spring
et al., 2000; Sims et al., 2004; Baurhoo et al., 2007). The
application of molecular techniques has allowed detailed
study of the composition of the intestinal microﬂora, giv-
ing us a more detailed picture of the complex changes
following MOS supplementation (Corrigan et al., 2010;
Horgan et al., 2010).
Effects of MOS on intestinal structure and function
A large surface area is the key for optimal digestive func-
tion and nutrient absorption, therefore the surface of the
small intestine should be covered with long healthy villi
(see Figure 3). Three studies have reported better energy
digestion when MOS was included in broiler diets, and
several studies with MOS in poultry have shown longer
villi with shallower crypts (Iji et al., 2001; Yang et al.,
2008a; Baurhoo et al., 2009). Comparable changes in
intestinal structure have also been reported in ﬁsh. In
rainbow trout, supplementing the diet with 0.2% level
of MOS resulted in an increase in gut surface area, micro-
villi length and density, and favourably altered microbial
populations (Dimitroglou et al., 2009).
A shallow crypt is a good indicator of a healthy and
efﬁcient small intestine, as it then requires fewer nutrients
for renewal. With a lower renewal rate, the intestinal cells
become more mature, allowing for more efﬁcient digest-
ive enzyme production and nutrient absorption. Research
has shown increased production of enzymes such as;
maltase, leucine aminopeptidase, and alkaline phosphat-
ase in the brush border lining the intestines of animals
supplemented with MOS (Ferket, 2002; Yang et al.,
2008b).
To protect the villi and intestinal surface, the gut pro-
duces more mucus from speciﬁc cells called goblet cells.
In general, the number of goblet cells is an indicator of
mucus production, and researchers have found that gob-
let cell numbers were increased with MOS. The import-
ance of such changes for animal health is still being
debated by scientists.
MOS as a nutritional supplement for companion
animals and horses
MOS is included in diets for horses, dogs, cats, rabbits
and pet birds by feed manufacturers mainly due to its
beneﬁts for their health. As a nutritional supplement,
MOS offers a natural approach to support the microﬂora
and thus improve overall health, well-being and longevity.
Two studies from the University of Florida (Spearman
et al., 2004; Ott, 2005), involving horses supplemented
with MOS, showed that pregnant mares responded
with increased levels of immunoglobulin in their blood,
and produced colostrum with higher levels of IgG,
IgM and IgA. Consequently, higher Ig transfer to the
foal via colostrum from the mare can ensure better resist-
ance to pathogens prevalent in the environment. Ott,
(2005) demonstrated this beneﬁt when he showed that
foals issued from mare fed MOS tended to have less
Figure 3. Structure of small intestine
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incidence of diarrhoea. This study (Table 1) showed that
mares had signiﬁcantly higher IgA in blood, and, as a
consequence, numerically higher IgA in colostrum, milk
and in circulating levels from foals post partum compared
to negative and ribose supplemented control diets. MOS
may be useful in equine rations by helping young foals
receive high levels of antibodies through passive transfer
from colostrum and can also assist in promoting colon-
isation of the intestinal tract with beneﬁcial, symbiotic
organisms. Horses in training may beneﬁt from
improved immune response associated with supplemen-
tation of MOS, however this needs to be veriﬁed.
A number of trials have been carried out to explore the
efﬁcacy of MOS in improving gut health in dogs. To
reduce the risk of digestive upsets, it is critical to keep
the concentrations of potential pathogens low. MOS
has been shown to reduce faecal E. coli and C. perfringens
and tended to promote greater concentrations of beneﬁ-
cial Lactobacilli and Biﬁdobacteria spp. (Strickling et al., 2000;
Swanson et al., 2002a; Grieshop et al., 2004; Gouveia
et al., 2006). Older dogs tend to have reduced concentra-
tions of Biﬁdobacteria spp.(Grieshop et al., 2004), although
a signiﬁcant increase in Biﬁdobacteria spp. concentration
was noted with MOS supplementation of diets for senior
dogs, thus counteracting the negative effects of age on
colonic health (Grieshop et al., 2004).
The mechanism of action for reducing the numbers of
C. perfringens may differ from that previously explained
for bacteria with type-1-ﬁmbriae. Research in other spe-
cies has demonstrated that MOS has an effect on intes-
tinal morphology as well as both innate and acquired
immune system components, which may help to explain
the observed reductions in C. perfringens. Research shows
an increase in serum lymphocytes and lower plasma neu-
trophils when adult dogs were supplemented with MOS
and fructooligosacchides (FOS). FOS are chain polymers
of the sugar fructose that are found in a variety of foods.
These ﬁndings indicate an improvement in immunity
that, in turn, gives rise to increased protection against
intestinal pathogens (Swanson et al., 2002b). Other
areas of interest to dog owners are the effect of MOS
on nutrient digestibility and stool quality; both for health
and practical (poop-a-scoop) reasons (Zentek et al., 2002;
Kappel et al., 2004).
In terms of immunity, a study by O’Carra (2007) used
six collie puppies which were fed a control diet or supple-
mented with 2 g MOS per kg of feed, and the effects on
humoral (plasma IgG level) and innate immunity (neu-
trophil activity and blood lysozyme concentration) exam-
ined. The puppies were vaccinated on day seven and
given booster shots on days 21 and 35. The main effect
determined in this study was on innate immunity, where
circulating neutrophil numbers were higher in dogs fed
MOS, indicating a heightened defence against bacterial
infection (Figure 4).
Table 1. Influence of feeding MOS in diets on mare IgA immunity (Ott 2006).
Parameter Treatment Time relative to foaling
−28d foaling +28d +56d Colostrum Milk d3
IgA mare Control 401 490 499 506 133 35
Ribose 381 415 469 489 117 54
MOS 694 719 721 809 170 74
P 0.03 0.01 0.06 0.007 0.73 0.71
Foaling 7 d 14 d 28 d 56 d
IgA foal Control 254 168 38 38 52
Ribose 234 142 52 43 70
MOS 374 191 54 43 88
P 0.29 0.60 0.71 0.86 0.37
Figure 4. Number of circulating active neutrophils (O’Carra 2007) measured
as the number of active neutrophils per microscope field (x40)
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Rabbits may be considered both a farm and a compan-
ion animal. Research trials in rabbits have shown that,
out of 20 trials conducted, improvements in weight
gain, FCR and reductions in mortality are typically
observed, leading to better performance and lower
costs of production.
MOS as a nutritional supplement for farm animals
Mannan oligosaccharides have been widely evaluated in
feeding trials. As animal health and performance are
inﬂuenced by many factors other than nutrition, the
responses to a feed supplement will vary between pro-
duction systems. Diet composition (mainly ﬁbre content)
may interact with supplemental MOS. Therefore, a con-
cept such as MOS should not be evaluated based on sin-
gle trials. Meta-analyses, which summarise a large
number of published research trials, allows for a more
comprehensive overview.
MOS for poultry
The ﬁrst study testing MOS in poultry (Iji et al., 2001)
that showed an improvement in performance was
published in 2001. The data showed better feed conver-
sion, indicating that birds were converting feed more
efﬁciently into body tissue. An efﬁcient feed conversion
ratio (FCR) is important for overall performance and
economics of production and thus is a key contributing
factor to sustainable poultry rearing. Over the years, a
series of papers have documented performance effects
under different production conditions were published.
Hooge (2004a) summarised 44 trials in a meta-analysis
where MOS was fed between 0.5 and 2 kg/tonne of
feed. He concluded that, on average, MOS led to a
1.95% improvement in body weight, 2.25% improve-
ment in FCR and nearly 22% lower bird mortality.
Rosen (2007a) reported similar effects in his holo-
analysis reviewing 82 trials, where the various feed and
trial site factors were also taken into account. Table 3
shows the results of various metanalyses of broiler per-
formance responses to MOS.
After chicken, turkey is the second most important
source of poultry meat globally. In turkeys, 76 compari-
sons have shown similar responses to MOS as in broilers
(Hooge, 2004b; Rosen, 2007b). Hooge (2004b) reported
that MOS addition in turkey feed resulted in an average
2% increase in body weight (P = 0.01), a reduction of
FCR by 1.5% (P = 0.172) and 25% less mortality (P =
0.016) when analysing data from all trials run from
1993-2003 (Table 4). Table 5 below (Rosen, 2007b)
shows the equations relating to main factors inﬂuencing
the response of turkeys to MOS addition in feeds –
these equate to 57 g increase in body weight, 1.6 points
better FCR and 1.3% improved liveability in birds fed
MOS. Several studies have suggested that MOS, when
added to poultry diets, allowed the birds to perform at
a similar level as when fed a diet supplemented with
AGPs (Parks et al., 2001; Sims et al., 2004; Parks et al.,
2005).
Table 2. Body weight gain, feed conversion ratio, and mortality of rabbits
fed a control diet or one supplemented with MOS.
Parameter
Days on
test Control MOS
%
difference
P
value
Body weight (kg) 38.4 1.357b 1.419a +4.6 0.001
FCR 38.4 4.175a 3.963b −5.1 0.001
Mortality (%) 38.5 17.8z 9.1b −49.0 0.004
Table 3. Metanalysis of broiler trials showing average responses to MOS supplementation (Hooge, 2004a).
Parameter Trials Average age (days) Negative control MOS % Difference
Body weight (kg) 34 42.2 2.147b 2.190a +1.95
FCR 34 42.2 1.879a 1.837b −2.25
Mortality (%) 19 42.6 5.582a 4.366b −21.78
Means in rows not sharing a letter differ significantly (P < 0.05)
Table 4. Average responses to MOS supplementation in turkey diets (Hooge, 2004)
Trials Average age (days) Negative control Bio-Mos % Difference
Body wt, kg 27 68.7 5.65b 5.78a +2.25
FCR 23 72.9 1.981 1.949 −1.62
Mortality % 16 72.1 10.329a 7.784b −24.64
Means in rows not sharing a letter differ significantly (P < 0.05)
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MOS for pigs
An important factor in the successful start of a piglet’s
life is the consumption of sufﬁcient, high quality colos-
trum, and the Ig it contains. Igs in colostrum protect
the piglet from harmful diseases in the ﬁrst weeks of
its life, before it attains its own ‘acquired’ immunity.
Several studies have looked at supplementing sow diets
with MOS with the aim of improving the health of the
sows. A healthy sow produces good quality colostrum
and spreads less harmful bacteria in the environment
where she gives birth and raises piglets. Several research-
ers (Newman et al., 2001; Quinn et al., 2001; Le Dividich
et al., 2009) reported a signiﬁcant increase in colostrum
production and quality in sows fed MOS. These changes
most likely explain a reduced pre-weaning mortality and a
higher litter size and piglet weight at weaning (Le
Dividich et al., 2009). A review of published literature
showed that the mortality of young piglets was reduced
when MOS was supplemented in the diets of the sow
(Le Dividich et al., 2009). Keeping the mortality of
young piglets to a minimum is important from an animal
welfare stance as well as from an economic point of view.
The other critical phase in a piglet’s life is at weaning,
when it is separated from the sow. Moving from a pre-
dominantly milk diet to compound feed leads to potential
disruption in the intestinal microﬂora and presents a
higher risk of intestinal disorders. Two meta-analyses,
involving a total of 123 comparisons (Miguel et al.,
2004; Rosen, 2006) concluded that performance was bet-
ter in piglets fed MOS-supplemented feed (Table 6). The
data indicated that piglets which were particularly chal-
lenged during this transition phase (with a slower growth
rate due to the challenge), responded particularly well to
MOS supplements. Positive performance effects with
MOS have been reported in later production phases,
but appear to be smaller in magnitude compared to
responses seen in very young animals (Miguel et al., 2004).
From overall metanalysis of ten years of pig trial data,
Rosen (2006) showed that 73% of trials showed better
weight gain and 68% improved FCR. This equated to
15 g per day extra growth (3.6%), 7.5 g/d better feed
intake (1%) and 5.3 point reduction in FCR (3%).
MOS for calves
The health status of young calves is one of the most
important factors contributing to growth and perform-
ance, hence the ﬁrst trial to study the effects of MOS
in feed was conducted on young bull calves (Newman
et al., 1993), which showed improved intake and, sub-
sequently, better growth rates. Diarrhoea in young calves
is a major issue in the dairy sector, and can be caused by
viral or bacterial infections, however, E.coli is often
involved. As MOS can bind E. coli, it can modify and
help to improve the composition of the intestinal
microﬂora. This premise was demonstrated as a reduc-
tion in faecal E. coli counts (Jacques et al., 1994) and
improvements in faecal score (Lazarevic et al., 2010;
Morrison et al., 2010) in calves fed diets containing
MOS. These improvements were coupled with an
increase in concentrate (commercial compound feed)
intake (Heinrichs et al., 2003) and better growth perform-
ance (Newman et al., 1993; Quigley, 1996; Dvorak et al.,
1997; Sellars et al., 1997). In addition to the changes in
the gut, several authors noticed improvements in respira-
tory health, which can also contribute to better perform-
ance (Newman et al., 1993; Sellars et al., 1997).
Conversely, one trial reported no effects on liveweight
gain despite increased feed intake (Terre et al., 2007).
The transfer of immunity from cow to calf is critical in
order to convey protection from many different diseases
(Morrisson et al., 2010). Dairy cows fed MOS had better
immune protection against rotavirus and were able to
Table 5. Equations for 33 (24 for mortality) trial results investigating the influence of MOS in feed on performance parameters of growing turkeys (P < 0.05)
(Rosen, 2007b).
Effect of MOS on: Equation R2 RMSE n
Feed intake FDIeff = 207− 0.048c FDIC + 1057a DISC 0.395 881 33
Live weight gain LWGeff = 4933a −49.0a EXDAT 0.130 244 33
FCR FCReff =− 3.061c −0.0904b FCRC + 0.0325c EXDAT 0.228 0.067 82
Mortality MORTeff = 0.990− 0.277a MORTC + 2.83a AB + 11.5c VET 0.795 2.67 24
aP < 0.05, b P < 0.01, c P < 0.001
Table 6. Metanalysis of impact of feeding MOS to growing pigs (Miguel,
2004).
Parameter No. studies
Difference from
control % Significance
Daily weight gain 54 +4.1 <0.001
Feed intake 54 +2.1 0.003
FCR 54 −2.3 <0.001
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pass some of this protection on to their calves. Results
have indicated that supplementation with MOS to cows
during their dry period enhanced immune response to
rotavirus and tended to enhance the subsequent transfer
of rotavirus antibodies to calves (Franklin et al., 2005).
A study at Penn State University compared calves fed
MOS (4 g/day) to those receiving antibiotics (neomycin
and oxytetracycline) or a negative control in milk replacer
for up to six weeks of age (Heinrichs et al., 2003). They
concluded that MOS was equally as effective in improv-
ing faecal scores (faecal ﬂuidity, scour severity and faecal
consistency) as the antibiotics, leading them to conclude
that the MOS could replace antibiotics in milk replacer
formulation.
Terre et al. (2007) examined the effect of MOS in milk
replacer on calf health in an enhanced-growth feeding
program. Inclusion of MOS stimulated starter feed intake
post-weaning and resulted in a signiﬁcant reduction in
Cryptosporidium spp in the ﬁrst week of supplementation.
Further research in Australia (Quezada et al., 2007)
demonstrated positive effects on intestinal morphology
with the inclusion of MOS in the milk replacer from
two to 21 days of age. Serum IgG losses were reduced
with supplementation and villi height increased in the
ileum. The defence functions of the Peyer’s patches,
gut regions which ‘sample’ ingesta for pathogenic pres-
ence, were enhanced through greater numbers of T
cells. MOS also facilitates changes in the mucous produc-
tion from the intestinal lining, improving direct physical
barrier to infection. This could be due to the upregulation
of gene expression in crypt cells and brush border trans-
porter proteins (Uni, 2007). Greater mucous production
allows for better protection against pathogen attachment
and enhanced nutrient uptake.
These beneﬁts of MOS in the diet of pre-weaned
calves are not only restricted to health. Hooge (2006) car-
ried out a meta-analysis of 17 studies where MOS was
incorporated into milk replacer, and reported an average
improvement in weight gain of 15%, equating to a daily
weight gain increase of 70 g per day (Table 7).
MOS in Aquaculture
Farmed ﬁsh larvae are often fed with live feed cultures,
which, due to their intensive nature, provide ideal condi-
tions for the growth of opportunistic pathogens. MOS
incorporation into live feeds has been studied to assess
the impact on microbial load and showed a reduction
in Vibrio spp. levels in live feed cultures (Daniels et al.,
2006; Daniels et al., 2010; Dimitroglou et al., 2011).
These reductions were likely due to the agglutination or
binding of Vibrio cells to MOS, mediated by the presence
of mannose receptors. In addition, MOS supplementa-
tion has been shown to reduce the overall cultivable
intestinal microbial load and to enhance bacterial species
variety (Dimitroglou et al., 2009).
Several researchers have reported improved perform-
ance and feed efﬁciency with MOS in aqua culture
(Spearman et al., 2004; Staykov et al., 2007). As in terres-
trial animals, changes have been associated with effects
on the gut and the immune system. Dimitroglou et al
(2010) observed alterations of circulating leukocytes pro-
portions as well as increased total leucocyte levels when
feeding gilthead sea bream. Torrecillas et al. (2007;
2010) assessed the dietary inclusion of various levels of
MOS on the immune status and disease resistance of
sea bass; Rodriguez-Estrada et al. (2009) performed simi-
lar studies in rainbow trout using MOS, a probiotic and
an acid organic. MOS reduced Vibrio alginolyticus, V. angu-
illarum and Listonella anguillarum, two important pathogens
in aqua ﬁsh.
The next generation: Mannan Rich Fraction (MRF)
Research in recent years led to the identiﬁcation and con-
centration of unique sugars present in the cell wall of a
speciﬁc strain of Saccharomyces cerevisiae, which has resulted
in the development of the next generation of MOS tech-
nology, Mannan Rich Fraction (Actigen®, Alltech Inc.,
USA). This fraction is quantiﬁable in both premix and
feed using a unique in-feed ELISA test. Another tech-
nique, ELISA Linked Mucin Adherence Assay (known
as ELMAA) detects and evaluates the efﬁcacy of the
product in premix and complete feed. These tests allow
for improved quality assurance, traceability and consist-
ency of response. This second-generation bioactive
mannan-rich fraction (MRF) has been shown to block
unfavourable organisms from the gut. This carbohydrate
supports nutrient utilisation, maintains digestive function
and enzyme activity, controls inﬂammation and reduces
the gap between ideal and actual performance (Xiao
Table 7. Metanalysis of benefits in calf performance from feeding MOS
(Hooge, 2006).
Parameter Trials Control MOS Difference %
Body weight 16 22.8 26.2 +15.0
Feed intake 16 22.3 24.5 +14.6
Weight gain 8 478 548 +9.8
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et al., 2010; Che et al., 2012; Samuel et al., 2012). These
mechanisms have been conﬁrmed by nutrigenomic
data. More puriﬁed than MOS, MRF provides a great
source of attachment for speciﬁc pathogens and, because
it is not digestible, it potentially ‘shuttles’ attached bac-
teria through the digestive tract, preventing colonisation.
MRF can be included in diets at lower inclusion rates
than MOS whilst still improving zootechnical perform-
ance under challenging ﬁeld conditions.
MRF results published by Che et al. (2012) at the
University of Illinois, showed that MRF is effective in
strengthening immune responses and improving nutrient
utilisation in challenged (infected with Porcine
Reproductive and Respiratory Virus) pigs. Importantly,
feeding MRF improved nutrient utilisation in infected
pigs during the critical time from 28 to 42 d post-
inoculation (P< 0.01).
Munyaka et al. (2012) showed that supplementing broil-
er chickens’ diet with MRF downregulated the gene
expression of toll-like receptors TLR4, cytokines
IL-12p35, interferon (IFN)-ϒ in the ileum and caecal
tonsils and cytokine IL-10 in the ileum and caecal tonsil
of broiler chickens. These immunity mediators are part
of two immune pathways, Th1-helpers and Th2 helpers,
and these results suggest anti-inﬂammatory responses in
broiler chickens. MRF may have beneﬁcial effects on
performance as well as immune modulation, through
mobilisation of heterophils, and improved gut
morphology.
A recent study performed by Johnson et al. (2013),
from the University of New England in Australia, inves-
tigated the efﬁcacy of MRF as a replacement for zinc
bacitracin and salinomycin, using a necrotic enteritis
challenge feeding study model. Supplementation did
not completely protect birds from necrotic enteritis or
coccidiosis lesions, although MRF was as effective as
the antibiotics in preventing performance decline from
coccidiosis. The patterns of lesion scores were in line
with the mode of action; zinc bacitracin was effective
against the gram+ Clostridia, salinomycin was speciﬁc
against Eimeria and MRF promoted immune stimulation
in the gut lumen. This study indicated that yeast based
MRF has promise as a tool for controlling necrotic
enteritis.
Meta-analyses involving MRF on broiler performance
have been published (Hooge, 2011; Hooge et al., 2013)
which showed the superiority of MRF compared to
MOS of their effects on broiler growth performance
(Table 8).
Conclusions
In comparison to other oligosaccharide fractions such as
fructo-oligosaccharides (FOS), the dataset on mannan-
oligosaccharides (MOS) is larger, more varied, and offers
a greater understanding of the application for this tech-
nology. With 733 publications (95% published with a
speciﬁc commercial fraction, Bio-Mos®), knowledge in
this area dwarfs that of other similar concepts and pro-
vides researchers with a myriad of possible applications.
With increasing restrictions on the use of antibiotic gut
microﬂora modiﬁers in animals and concerns with anti-
biotic resistance in humans, mannans provide a technol-
ogy platform which will be a critical part of the arsenal
for veterinarians and animal producers in the future.
MOS, due to cost of production, extraction technology
and potential inﬁnite supply, has been used widely in ani-
mal diets over the last 20 years, but are now being super-
seded by the next generation, MRF.
Further advances in the ﬁelds of nutrigenomics, pro-
teomics and metabolomics will enable researchers to
ask key questions about dietary ingredients and their
effects on an organism. By focusing on gene expression
and functional genomics, it will soon be possible to gain a
Table 8. Comparison of some meta-analyses involving MOS (Bio-Mos®) and MRF (ActigenTM) on broiler growth performance.
Reference (year)
Difference due to Bio-Mos or Actigen® vs. Control
Body weight kg (%) FCR (%) Mortality (%)1
Bio-Mos® or Actigen® diets vs. negative control
Hooge (2004) +0.038* / (+1.75) −0.035* / (−1.89) −0.759* / (−16.4)
Hooge (2011) +0.129 */ (+5.41) −0.046 */ (−2.54) −0.76 */ (−10.5)
Hooge (2013) +0.080 */ (+3.34) −0.033* / (−1.84) −0.80 */ (−12.5)
Bio-Mos® or Actigen® diets vs. antibiotic diets
Hooge (2004) −0.007 / (−0.32) −0.008 / (−0.11) −0.83 / (−18.1)
Hooge (2011) +0.016 / (+0.65) −0.003 / (−0.17) +0.57 / (+7.97)
Hooge (2013) −0.005 / (−0.19) 0 / (0) −0.05 / (−0.82)
* significantly different compared to the control
1Mortality % difference relative to the respective negative control or antibiotic control.
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more deﬁnitive understanding of the importance of diet-
ary intervention in nutritional strategies for disease resist-
ance and production efﬁciency.
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